publicly available sources. BMRN Dividend History & Description — BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Start a 14-day … The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. The technique has proven to be very useful for finding positive surprises. BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull Zacks - Fri Feb 26, 8:16AM CST Zacks Equity Research - ZACKS - Fri Feb 26, 8:16AM CST BioMarin (BMRN) beats estimates for both earnings and … Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Since then, BMRN stock has decreased … BioMarin Pharmaceutical (BMRN) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2020. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis, and Willard H Dere. BioMarin (BMRN) was a big mover last session, as the company saw its shares rise 7% on the day. BIOMARIN … This includes personalizing content and advertising. The price/operating cash flow metric for Biomarin Pharmaceutical Inc is higher than 96.85% of stocks in our set with a positive cash flow. This is an estimated date of earnings release. Zacks Equity Research - ZACKS - Thu Feb 18, 11:33AM CST BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Learn more. Receive a free world-class investing education from MarketBeat. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Find the latest Earnings Report Date for BioMarin Pharmaceutical Inc. Common Stock (BMRN) at Nasdaq.com. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. BioMarin Pharmaceutical (BMRN) closed the most recent trading day at $76.88, moving -0.84% from the previous trading session. BioMarin’s biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA in August 2020. Earnings, adjusted for one-time gains and costs, were 21 cents per share.The results topped Wall Street expectations. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. A high-level overview of BioMarin Pharmaceutical Inc. (BMRN) stock. NYSE and AMEX data is at least 20 minutes delayed. ALXN vs. BMRN: Which Stock Should Value Investors Buy Now? Their forecasts range from $77.00 to $218.00. The Ratings Breakdown table uses Zacks' brokerage recommendations. A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. This move was narrower than the S&P 500's daily loss of … Learn about financial terms, types of investments, trading strategies and more. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its earnings results on Thursday, February, 25th. BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index, BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET. View BioMarin Pharmaceutical's (NASDAQ:BMRN) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. One share of BMRN stock can currently be purchased for approximately $78.74. Volume reflects consolidated markets. MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Ten analysts surveyed by Zacks expected $447.2 million. BioMarin Pharmaceutical's management team includes the following people: CTO and Exec. According to . By comparison, BMRN has a P/B of 3.83. The monthly returns are then compounded to arrive at the annual return. Biomarin Pharmaceutical Inc (BMRN) Q3 2020 Earnings Call Transcript You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. BioMarin Pharmaceutical does not currently pay a dividend. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. View institutional ownership trends for BioMarin Pharmaceutical. View all of BMRN's competitors. BMRN Stock Predictions, Articles, and Biomarin Pharmaceuticals News. Please log in to your account or sign up in order to add this asset to your watchlist. BioMarin Pharmaceutical issued an update on its FY 2021 BMRN | Complete BioMarin Pharmaceutical Inc. stock news by MarketWatch. View analysts' price targets for BioMarin Pharmaceutical or view top-rated stocks among Wall Street analysts. BioMarin Pharmaceutical has a P/B Ratio of 4.53. View the latest BMRN stock quote and chart on MSN Money. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. By comparison, BMRN has a P/B of 3.94. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) stock price prediction is 171.632483 USD. Futures and Forex: 10 or 15 minute delay, CT. Market Data powered by Barchart Solutions. BioMarin Pharmaceutical has received 1,460 “outperform” votes. 8 Wall Street analysts that have issued a 1 year BMRN price target, the average BMRN price target is $103.75, with the highest BMRN stock price forecast at $125.00 and the lowest BMRN stock price forecast at $86.00. Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis and Willard H Dere. also free. Get prepared with the key expectations. On average, they anticipate BioMarin Pharmaceutical's share price to reach $117.36 in the next year. If you wish to go to ZacksTrade, click OK. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. completeness, timeliness, or correct sequencing of any of the Information on All rights reserved. Zacks Equity Research 02/18/2021 06:33 AM ET. Zacks Consensus Estimate This rare disease biopharmaceutical is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change … Biomarin Pharmaceutical Inc. - Registered Shares Stock Forecast, BMRN stock price prediction. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. Get the latest BioMarin Pharmaceutical Inc. BMRN detailed stock quotes, stock data, Real-Time ECN, charts, stats … The company provided earnings per share (EPS) guidance of for the period. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Research, Inc. nor its Information Providers can guarantee the accuracy, the Web site, including, but not limited to Information originated by Zacks The lowest sales … Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR). In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. BMRN stock was acquired by a variety of institutional investors in the last quarter, including Dodge & Cox, Norges Bank, Parnassus Investments CA, Avidity Partners Management LP, Janus Henderson Group PLC, UBS Asset Management Americas Inc., Alliancebernstein L.P., and Price T Rowe Associates Inc. MD. BioMarin generated total sales of $1.9 billion in 2020, up 9%. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. 01/26/21-10:40AM EST Zacks Stock … Export data to Excel for your own analysis. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. View real-time stock prices and stock quotes for a full financial overview. Find the latest BioMarin Pharmaceutical Inc. (BMRN) stock quote, history, news and other vital information to help you with your stock trading and investing. BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael CA, 94901. Click here to watch the full series. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. BioMarin Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Zacks Equity Research 02/11/2021 05:40 AM ET. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. View insider buying and selling activity for BioMarin Pharmaceutical or view top insider-selling stocks. The official website for BioMarin Pharmaceutical is www.bmrn.com. BioMarin Pharmaceutical (BMRN) closed the most recent trading day at $76.88, moving -0.84% from the previous trading session. Fundamental data provided by Zacks and Morningstar. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Regulatory applications for vosoritide, which has been developed for treating achondroplasia, the most common form of dwarfism, are under review in Europe and United States. Eight analysts have issued estimates for BioMarin Pharmaceutical'… Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). BioMarin Pharmaceutical has received 62.31% “outperform” votes from our community. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. The Zacks Rank has been called the Billion Dollar Secret. Neither Zacks Investment Information Providers, or gathered by Zacks Investment Research, Inc. from Zacks Rank Education -- Learn more about the Zacks Rank This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Story continues Real time BioMarin Pharmaceutical (BMRN) stock price quote, stock graph, news & analysis. Biomarin Pharmaceutical (NASDAQ:BMRN) is currently down 7.49% to a price of $78.33. See Zacks' prediction free. BIOMARIN INVESTIGATION INITIATED BY FORMER... BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN, Noteworthy Friday Option Activity: BMRN, ZNGA, ZYXI, Why Biomarin Pharmaceutical's Stock is Down During Today's Session, BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull, Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript, Biomarin Pharmaceutical Inc. Bottom Line Rises In Q4, Biomarin Pharmaceutical's Earnings Outlook, Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline, BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors. Biomarin Pharmaceutical Inc. - Registered Shares Stock Price Forecast, "BMRN" Predictons for2023 Learn everything you need to know about successful options trading with this three-part video course. ALXN vs. BMRN: Which Stock Is the Better Value Option? Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. Biomarin Pharmaceutical Inc. - Registered Shares Stock Price Forecast, "BMRN" Predictons for2024 The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. The company's average rating score is 2.58, and is based on 11 buy ratings, 8 hold ratings, and no sell ratings. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. For the BioMarin Pharmaceutical Inc forecast (traded under symbol BMRN) for one year forward price target at the top of this page, we have presented the average BMRN forecast for forward target price across the 16 analysts covering BMRN, as reported in data provided by Zacks Investment … Learn more about Zacks Equity Research reports, See all Medical - Biomedical and Genetics Peers ». With a market capitalization of $13,882,696,068, Biomarin Pharmaceutical Inc has a greater market value than 85.85% of US stocks. The price/operating cash flow metric for Biomarin … Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The rare disease biopharmaceutical posted revenue of $452.1 million in the period, also surpassing Street forecasts. This suggests a possible upside of 49.1% from the stock's current price. This move was narrower than the S&P 500's daily loss of 1.86%. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.Its two key late-stage investigational products are Roctavian/valoctocogene roxaparvovec/valrox (hemophilia A) and vosoritide (achondroplasia). The company's portfolio comprises six marketed products namely, Aldurazyme (mucopolysaccharidosis type I (MPS I)), Naglazyme (MPS VI), Kuvan (phenylketonuria (PKU) – a rare genetic enzyme deficiency disorder), Vimizim (MPS IVA or Morquio syndrome type A), Brineura (CLN2– a form of Batten disease) and Palynziq (PKU). BIOMARIN PHARMACEUTICAL Income Statement, Balance Sheet and Statement of Cash Flows. BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. According to analysts' consensus price target of $117.36, BioMarin Pharmaceutical has a forecasted upside of 49.1% from its current price of $78.74. View BioMarin Pharmaceutical Inc. BMRN investment & stock information. Zacks Rank Education -- Learn more about the Zacks Rank
Bbc Coventry And Warwickshire Radio Contact, Ark Funds 2021, Uva Tennis Schedule 2021, Scott Jacobs San Francisco, Bungy Jump Harbour Bridge, Ymca Overnight Camps California, Dvb Set Top Box Channel List, Festivals Au Québec,